Scientists believe combining navitoclax with ruxolitinib might help people with myelofibrosis. Within this demo fifty percent the people have navitoclax and ruxolitinib. One other 50 percent have ruxolitinib as well as a dummy drug (placebo ). The combination of navitoclax and irradiation exhibited a strong synergy regardless of the p53 https://delcasertib55432.targetblogs.com/26602247/what-does-olorofim-mean